Global Life Science Ventures — Investing in the life sciences

Global Life Science Ventures (GLSV) is a leading, independent venture capital fund focusing exclusively on the life sciences. GLSV is dedicated to supporting early-stage groups, originating from universities, scientific institutions or industry. The fund may also invest in selected later stage companies, including buy-outs. For this purpose, GLSV provides finance, advice and access to expertise and networks. The group currently advises and manages funds totalling more than € 200 million. With offices in Germany and Switzerland, GLSV acts as one team with a global perspective.

Profile
Team
Investment Practice
Portfolio
FAQ
Download Area
News
Events
Contact Us
Text size

GLSV news

22.04.2008 GLSV receives 2007 Dyodelta European Life Science Innovation Award "Investor of the Year Award" more...

14.04.2008 April 2008 Teil 20 der Serie: Köpfe der deutschsprachigen Private Equity-Szene, Hanns-Peter Wiese, Venture Capial Magazin 4/2008 more...

17.01.2008 GLSV leads investment in Action Pharma A/S more...

06.12.2007 GLSV invests in Pelikan Technologies more...

02.10.2007 Biotech Investment Barometer Reveals Continued Confidence in Sector
more...

More News


Portfolio company news

19.12.2008 NeurogesX Announces FDA Acceptance to Review New Drug Application for NGX-4010 to Treat Post-Herpetic Neuralgia more...

12.12.2008 Agendia’s MammaPrint® Predicts to Neoadjuvant Chemotherapy in Breast Cancer more...

09.12.2008 CombinatoRx Presents New Data on B-Cell Malignancy Programs more...

27.11.2008 MediGene: European Patent Office decides to grant new European Patent for Veregen® more...

22.10.2008 NeurogesX Submits NDA for NGX-4010 Dermal Capsaicin Patch for Treatment of Postherpetic Neuralgia (PHN) more...

More News